Trials of adjuvant radiotherapy and chemotherapy in endometrial cancer
| Trial | Enrollment | No. of patients | Eligibility | Randomization | 5-Year overall survival | 5-Year progression-free survival |
| Italian15 | 1990–1997 | 345 | Stage I–II with grade 3 tumor; stage III | Pelvic RT vs 5 x CAP | 69% vs 66% (NS) | 63% vs 63% (NS) |
| GOG-12214 | 1992–2000 | 396 | Stage III and IV, up to 2 cm residual disease after surgery allowed | Whole abdomen irradiation vs 8 x AP | 42% vs 55% (p<0.01) | 38% vs 50% (p<0.01) |
| Japanese16 | 1994–2000 | 385 | Stage I–II with >50% myometrial invasion | Pelvic RT vs 3 x CAP | 85% vs 87% (NS) | 84% vs 82% (NS) |
| NSGO/EORTC pooled with Iliade-III17 | 1996–2007 | 534, NSGO/EORTC 378 and Iliade 156 | NSGO/EORTC stage I–III; Iliade stage II–III | Pelvic RT vs pelvic RT and 4 x AP or TAP or TC or TEP | 75% vs 82% (p=0.07) | 69% vs 78% (p=0.02) |
| PORTEC-320 | 2006–2013 | 686 | Stage I–II with high-risk factors, stage III | Pelvic RT vs pelvic RT with 2 x CP followed by 4 x TC | 76% vs 81% (p=0.034) Stage III 69% vs 79% Serous EC 53% vs 71% | 69% vs 77% (p=0.016) Stage III 58% vs 71% Serous EC 47% vs 60% |
| GOG-24918 | 2009–2013 | 601 | Stage I–II with high-intermediate or high-risk factors | Pelvic RT vs VBT and 3 x TC | 87% vs 85% (NS) | 76% vs 76% (NS) |
| GOG-25821 | 2009–2014 | 736 | Stage III and IVa without residual disease up to 2 cm | Pelvic RT with 2 x CP followed by 4 x TC vs 6 x TC | 70% vs 73% (NS) | 59% vs 58% (NS) |
AP, doxorubicin plus cisplatin; CAP, cyclophosphamide, doxorubicin, and cisplatin; CP, cisplatin; EC, endometrial cancer; GOG, Gynaecologic Oncology Group; NS, not significant; NSGO/EORTC, Nordic Society of Gynecologic Oncology/European Organization for Research and Treatment of Cancer; PORTEC, Post Operative Radiation Therapy for Endometrial Carcinoma; RT, radiation therapy; TAP, doxorubicin, cisplatin, and paclitaxel; TC, paclitaxel plus carboplatin; TEP, paclitaxel, epirubicin, and cisplatin; VBT, vaginal brachytherapy.